The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.
Webinar Date/Time: Thu, Nov 14, 2024 11:00 AM EST
Webinar Date/Time: Tue, Jul 30, 2024 11:00 AM EDT
Vectura helps customers bring inhaled medicines to market with a combination of formulation science, device technology, and inhaled product development expertise.
Dry powder inhalers (DPIs) are an important delivery technology for inhaled medicines in both respiratory and non-respiratory disease areas. Andreas Meliniotis, director of device development at Vectura, helps navigate the complex area of DPI product development and highlights the key considerations for both novel- and generic-drug programs. Live: Wednesday, Jun. 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST On demand available after final airing Jun. 24, 2021 Register free
Published: July 10th 2024 | Updated:
Published: June 24th 2020 | Updated:
